ACCESS Newswire

MicroVision, Inc.

27.4.2022 22:21:08 CEST | ACCESS Newswire | Press release

Share
MicroVision Announces First Quarter 2022 Results

REDMOND, WA / ACCESSWIRE / April 27, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2022 results.

"We made significant progress in the first quarter of 2022. We track tested our integrated Long Range Lidar sensor and perception software, demonstrating promising ground-truth data of our high-fidelity/low-latency solution at speeds of over 60 mph," said Sumit Sharma, MicroVision's Chief Executive Officer. "We continue to receive positive feedback and interest from automotive OEMs and Tier 1 suppliers for our best-in-class product with cost advantages."

"We began our testing in the U.S. and expect to conduct several more rounds of tests of our high-speed Highway Pilot system both in the U.S. and Germany during the second quarter as we work to deliver on our 2022 objectives," continued Sharma.

Key Financial Highlights for Q1 2022

  • Revenue for the first quarter of 2022 was $0.4 million, compared to $0.5 million for the first quarter of 2021.
  • Net loss for the first quarter of 2022 was $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $6.2 million, or $0.04 per share, which includes $1.6 million of non-cash, share-based compensation expense, for the first quarter of 2021.
  • Adjusted EBITDA for the first quarter of 2022 was negative $9.0 million, compared to negative $4.3 million in the first quarter of 2021.
  • Cash used in operations for the first quarter of 2022 was $10.9 million, compared to cash used in operations for the first quarter in 2021 of $4.5 million.
  • The Company ended the first quarter of 2022 with $103.3 million in cash and cash equivalents including investment securities, compared to $115.4 million at the end of December 31, 2021.

Conference Call and Webcast: Q1 2022 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Wednesday, April 27, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on April 27, 2022.

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.

About MicroVision

MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.

For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisionincor follow MicroVision on Twitter at @MicroVision.

MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Non-GAAP information

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.

MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.

Forward-Looking Statements

Certain statements contained in this release, including the Company's plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.
Balance Sheet
(In thousands)
(Unaudited)

March 31, December 31,
2022 2021
Assets
Current Assets
Cash and cash equivalents
$55,611 $82,647
Investment securities, available-for-sale
47,651 32,720
Inventory
1,815 1,780
Other current assets
1,865 2,283
Total current assets
106,942 119,430
Property and equipment, net
3,248 3,026
Operating lease right-of-use asset
5,368 5,577
Restricted cash
1,092 1,092
Intangible assets, net
105 115
Other assets
1,014 985
Total assets
$117,769 $130,225
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable
$1,919 $3,584
Accrued liabilities
1,288 1,170
Contract liabilities
4,915 5,265
Other current liabilities
474 1,181
Current portion of long-term debt
98 392
Current portion of operating lease liability
686 849
Current portion of finance lease obligations
24 21
Total current liabilities
9,404 12,462
Operating lease liability, net of current portion
4,882 4,983
Finance lease obligations, net of current portion
15 26
Total liabilities
14,301 17,471
Commitments and contingencies
Shareholders' Equity
Common stock at par value
165 164
Additional paid-in capital
746,028 742,042
Accumulated other comprehensive loss
(124) (19)
Accumulated deficit
(642,601) (629,433)
Total shareholders' equity
103,468 112,754
Total liabilities and shareholders' equity
$117,769 $130,225

MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)

Three months ended March 31,
2022 2021
Product revenue
$- $-
License and royalty revenue
350 479
Total revenue
350 479
Cost of product revenue
4 (5)
Total cost of revenue
4 (5)
Gross margin
346 484
Research and development expense
7,593 4,462
Sales, marketing, general and administrative expense
5,877 2,247
Total operating expenses
13,470 6,709
Loss from operations
(13,124) (6,225)
Other expense, net
(44) (6)
Net loss
$(13,168) $(6,231)
Net loss per share - basic and diluted
$(0.08) $(0.04)
Weighted-average shares outstanding - basic and diluted
164,563 155,454

MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)


Three months ended March 31,

2022 2021






GAAP net loss
$(13,168) $(6,231)
Add Interest (net)
(31) 5
Add Income taxes
- -
Add Depreciation & amorization
483 299
Add Share-based compensation expense
3,734 1,638
Adjusted EBITDA
$(8,982) $(4,289)

Investor Relations Contact

Jeff Christensen and Matt Kreps
Darrow Associates Investor Relations
MVIS@darrowir.com

SOURCE: MicroVision, Inc.



View source version on accesswire.com:
https://www.accesswire.com/699143/MicroVision-Announces-First-Quarter-2022-Results

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AI Trading Changing Stock, Gold, and Forex Trading Market: Funds Coin's Multi-Agent Trading Update Dominates20.5.2026 11:00:00 CEST | Press release

DENVER, CO / ACCESS Newswire / May 20, 2026 / Ten years ago, algorithmic trading was the exclusive territory of investment banks and hedge funds. Today, a retail trader with $100 and a smartphone can access the same class of automated execution that once required a team of quants and millions in infrastructure. That's not an exaggeration. It's the shift that's quietly reshaping stock and forex markets, and AI trading agents are at the center of it. The Old Way Is Breaking Down Manual trading made sense when markets moved slowly enough for humans to keep up. That world no longer exists. Forex markets process over $7 trillion in daily volume. Crypto trades around the clock across hundreds of exchanges. Stock prices react to news in milliseconds. The information moves faster than any individual trader can process, and emotions, such as fear, greed, and hesitation, make an already difficult job even harder. The traders who thrived in this environment were either exceptionally disciplined o

Karbon-X and Evertrak Sign Letter of Intent to Advance Infrastructure-Linked Plastic Waste Reduction Credit Initiative19.5.2026 19:45:00 CEST | Press release

Proposed initiative would evaluate the potential generation of Verra-aligned Plastic Waste Reduction Credits for approximately 200,000 railroad ties made from recycled plastic currently installed across railroad infrastructure in North America. CALGARY, AB / ACCESS Newswire / May 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary environmental markets, today announced the signing of a Letter of Intent with Evertrak LLC ("Evertrak"), the leading manufacturer of Glass Fiber Reinforced Composite (GFRC) railroad ties made from recycled plastic, to explore an infrastructure-linked Plastic Waste Reduction Credit ("PWRC") initiative under Verra's Plastic Waste Reduction (PWR) Standard. Across North America, 20 million railroad ties made from wood are replaced annually. Approximately 4-6 million of those ties are less than 12 years old. Safe, resilient, and efficient railroad infrastr

AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release

Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we

Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release

Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging

Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release

Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye